The most important selection criterion for PSMA RLT is sufficient expression of PSMA in tumor manifestation sites, as assessed by PSMA positron emission tomography/computer tomography (PSMA PET/CT) [9]. This evidence concerns the gene FOLH1 and neoplasm.